Literature DB >> 23455927

Why tazobactam and sulbactam have different intermediates population with SHV-1 β-lactamase: a molecular dynamics study.

Rui Li1, Yeng-Tseng Wang, Cheng-Lung Chen.   

Abstract

The imine intermediates of tazobactam and sulbactam bound to SHV-1 β-lactamase were investigated by molecular dynamics (MD) simulation respectively. Hydrogen bond networks around active site were found different between tazobactam and sulbactam acyl-enzymes. In tazobactam imine intermediate, it was observed that the triazolyl ring formed stable hydrogen bonds with Asn170 and Thr167. The results suggest that conformation of imine determined the population of intermediates. In imine intermediate of tazobactam, the triazolyl ring is trapped in Thr_Asn pocket, and it restricts the rotation of C5-C6 bond so that tazobactam can only generate trans enamine intermediate. Further, conformational cluster analyses are performed to substantiate the results. These findings provide an explanation for the corresponding experimental results, and will be potentially useful in the development of new inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455927     DOI: 10.1007/s00894-013-1802-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  16 in total

Review 1.  Catalytic properties of class A beta-lactamases: efficiency and diversity.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 2.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 3.  Inactivation of antibiotics and the dissemination of resistance genes.

Authors:  J Davies
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

4.  X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.

Authors:  P Swarén; D Golemi; S Cabantous; A Bulychev; L Maveyraud; S Mobashery; J P Samama
Journal:  Biochemistry       Date:  1999-07-27       Impact factor: 3.162

5.  Inhibition of beta-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies.

Authors:  C C Chen; O Herzberg
Journal:  J Mol Biol       Date:  1992-04-20       Impact factor: 5.469

6.  High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.

Authors:  Pius S Padayatti; Marion S Helfand; Monica A Totir; Marianne P Carey; Paul R Carey; Robert A Bonomo; Focco van den Akker
Journal:  J Biol Chem       Date:  2005-07-29       Impact factor: 5.157

7.  Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.

Authors:  Deley Sulton; Doritza Pagan-Rodriguez; Xiang Zhou; Yiding Liu; Andrea M Hujer; Christopher R Bethel; Marion S Helfand; Jodi M Thomson; Vernon E Anderson; John D Buynak; Lily M Ng; Robert A Bonomo
Journal:  J Biol Chem       Date:  2005-06-29       Impact factor: 5.157

8.  Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution.

Authors:  C Jelsch; L Mourey; J M Masson; J P Samama
Journal:  Proteins       Date:  1993-08

9.  Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.

Authors:  Monica A Totir; Marion S Helfand; Marianne P Carey; Anjaneyulu Sheri; John D Buynak; Robert A Bonomo; Paul R Carey
Journal:  Biochemistry       Date:  2007-07-13       Impact factor: 3.162

10.  Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.

Authors:  Marion S Helfand; Monica A Totir; Marianne P Carey; Andrea M Hujer; Robert A Bonomo; Paul R Carey
Journal:  Biochemistry       Date:  2003-11-25       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.